Brickell starts pivotal Phase III trial of drug candidate in U.S.
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) has kicked off its final clinical trial in the U.S. for its anti-underarm […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
Brickell Biotech launches brand reset amid positioning pivot
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, has launched a new brand, logo and website as…
Biotechnology boom
The COVID-19 pandemic — and its seemingly never-ending aftermath — has been a nightmare for commercial landlords of many different…
ARCA Biopharma submits anti-blood clotting drug to FDA as potential COVID treatment
WESTMINSTER — Gene therapy maker ARCA biopharma Inc. (Nasdaq: ABIO) has filed an initial application to study whether its anti-blood…
Brickell Biotech says flagship drug candidate reached long-term efficacy in trials
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) said its flagship anti-underarm-sweating treatment provided long-term efficacy in a Phase III trial…